Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease

Michelle M. Mielke; Matthew Anderson; J. Wesson Ashford; Andreas Jeromin; Pei Jung Lin; Allyson Rosen; Jamie Tyrone; Lawren Vandevrede; Deanna R. Willis; Oskar Hansson; Ara S. Khachaturian; Suzanne E. Schindler; Joan Weiss; Richard Batrla; Sasha Bozeat; John R. Dwyer; Drew Holzapfel; Daryl Rhys Jones; James F. Murray; Katherine A. Partrick; Emily Scholler; George Vradenburg; Dylan Young; Joel B. Braunstein; Samantha C. Burnham; Fabricio Ferreira de Oliveira; Yan Helen Hu; Soeren Mattke; Zul Merali; Mark Monane; Marwan Noel Sabbagh; Eli Shobin; Michael Weiner; Chinedu T. Udeh-Momoh

doi:10.1002/alz.14184

Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease

Michelle M. Mielke, Matthew Anderson, J. Wesson Ashford, Andreas Jeromin, Pei Jung Lin, Allyson Rosen, Jamie Tyrone, Lawren Vandevrede, Deanna R. Willis, Oskar Hansson, Ara S. Khachaturian, Suzanne E. Schindler, Joan Weiss, Richard Batrla, Sasha Bozeat, John R. Dwyer, Drew Holzapfel, Daryl Rhys Jones, James F. Murray, Katherine A. PartrickEmily Scholler, George Vradenburg, Dylan Young, Joel B. Braunstein, Samantha C. Burnham, Fabricio Ferreira de Oliveira, Yan Helen Hu, Soeren Mattke, Zul Merali, Mark Monane, Marwan Noel Sabbagh, Eli Shobin, Michael Weiner, Chinedu T. Udeh-Momoh

Research output: Contribution to journal › Article › peer-review

Abstract

Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients.

Original language	English
Pages (from-to)	8216-8224
Number of pages	9
Journal	Alzheimer's and Dementia
Volume	20
Issue number	11
DOIs	https://doi.org/10.1002/alz.14184
Publication status	Published - 2024 Nov

Subject classification (UKÄ)

Neurosciences

Free keywords

Alzheimer's disease
amyloid
biomarker
blood-based biomarkers
clinical implementation
clinical practice
cognitive impairment
disease-modifying treatment
patient journey
primary care
secondary care

Access to Document

10.1002/alz.14184

Cite this

Mielke, M. M., Anderson, M., Ashford, J. W., Jeromin, A., Lin, P. J., Rosen, A., Tyrone, J., Vandevrede, L., Willis, D. R., Hansson, O., Khachaturian, A. S., Schindler, S. E., Weiss, J., Batrla, R., Bozeat, S., Dwyer, J. R., Holzapfel, D., Jones, D. R., Murray, J. F., ... Udeh-Momoh, C. T. (2024). Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 20(11), 8216-8224. https://doi.org/10.1002/alz.14184

@article{177e4597735043169c8d4ca8c259b93b,

title = "Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease",

abstract = "Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients.",

keywords = "Alzheimer's disease, amyloid, biomarker, blood-based biomarkers, clinical implementation, clinical practice, cognitive impairment, disease-modifying treatment, patient journey, primary care, secondary care",

author = "Mielke, {Michelle M.} and Matthew Anderson and Ashford, {J. Wesson} and Andreas Jeromin and Lin, {Pei Jung} and Allyson Rosen and Jamie Tyrone and Lawren Vandevrede and Willis, {Deanna R.} and Oskar Hansson and Khachaturian, {Ara S.} and Schindler, {Suzanne E.} and Joan Weiss and Richard Batrla and Sasha Bozeat and Dwyer, {John R.} and Drew Holzapfel and Jones, {Daryl Rhys} and Murray, {James F.} and Partrick, {Katherine A.} and Emily Scholler and George Vradenburg and Dylan Young and Braunstein, {Joel B.} and Burnham, {Samantha C.} and {de Oliveira}, {Fabricio Ferreira} and Hu, {Yan Helen} and Soeren Mattke and Zul Merali and Mark Monane and Sabbagh, {Marwan Noel} and Eli Shobin and Michael Weiner and Udeh-Momoh, {Chinedu T.}",

year = "2024",

month = nov,

doi = "10.1002/alz.14184",

language = "English",

volume = "20",

pages = "8216--8224",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Wiley",

number = "11",

}

Mielke, MM, Anderson, M, Ashford, JW, Jeromin, A, Lin, PJ, Rosen, A, Tyrone, J, Vandevrede, L, Willis, DR, Hansson, O, Khachaturian, AS, Schindler, SE, Weiss, J, Batrla, R, Bozeat, S, Dwyer, JR, Holzapfel, D, Jones, DR, Murray, JF, Partrick, KA, Scholler, E, Vradenburg, G, Young, D, Braunstein, JB, Burnham, SC, de Oliveira, FF, Hu, YH, Mattke, S, Merali, Z, Monane, M, Sabbagh, MN, Shobin, E, Weiner, M & Udeh-Momoh, CT 2024, 'Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease', Alzheimer's and Dementia, vol. 20, no. 11, pp. 8216-8224. https://doi.org/10.1002/alz.14184

TY - JOUR

T1 - Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease

AU - Mielke, Michelle M.

AU - Anderson, Matthew

AU - Ashford, J. Wesson

AU - Jeromin, Andreas

AU - Lin, Pei Jung

AU - Rosen, Allyson

AU - Tyrone, Jamie

AU - Vandevrede, Lawren

AU - Willis, Deanna R.

AU - Hansson, Oskar

AU - Khachaturian, Ara S.

AU - Schindler, Suzanne E.

AU - Weiss, Joan

AU - Batrla, Richard

AU - Bozeat, Sasha

AU - Dwyer, John R.

AU - Holzapfel, Drew

AU - Jones, Daryl Rhys

AU - Murray, James F.

AU - Partrick, Katherine A.

AU - Scholler, Emily

AU - Vradenburg, George

AU - Young, Dylan

AU - Braunstein, Joel B.

AU - Burnham, Samantha C.

AU - de Oliveira, Fabricio Ferreira

AU - Hu, Yan Helen

AU - Mattke, Soeren

AU - Merali, Zul

AU - Monane, Mark

AU - Sabbagh, Marwan Noel

AU - Shobin, Eli

AU - Weiner, Michael

AU - Udeh-Momoh, Chinedu T.

PY - 2024/11

Y1 - 2024/11

N2 - Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients.

AB - Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients.

KW - Alzheimer's disease

KW - amyloid

KW - biomarker

KW - blood-based biomarkers

KW - clinical implementation

KW - clinical practice

KW - cognitive impairment

KW - disease-modifying treatment

KW - patient journey

KW - primary care

KW - secondary care

U2 - 10.1002/alz.14184

DO - 10.1002/alz.14184

M3 - Article

C2 - 39351838

AN - SCOPUS:85205494218

SN - 1552-5260

VL - 20

SP - 8216

EP - 8224

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 11

ER -